![](https://investorshub.advfn.com/uicon/103326.png?cb=1612221684)
Wednesday, May 30, 2018 8:43:36 AM
$22 million of non-tradeable warrants [not CVM-WS] likely profitably exercised in recent weeks [$35 million not exercised}
Warrants
Series DD 12/8/2016 1,360,960 $4.50 7/1/2018
Series EE 12/8/2016 1,360,960 $4.50 7/1/2018
Series N 8/18/2008 85,339 $3.00 8/18/2018 [likely exercised|
Series S 10/11/13- 10/24/14 1,037,120 $3.00 10/11/2018
Series V 5/28/2015 810,127 $19.75 5/28/2020
Series W 10/28/2015 688,930 $16.75 10/28/2020
Series X 1/13/2016 120,000 $9.25 1/13/2021
Series Y 2/15/2016 26,000 $12.00 2/15/2021
Series ZZ 5/23/2016 20,000 $13.75 5/18/2021
Series BB 8/26/2016 16,000 $13.75 8/22/2021
Series Z 5/23/2016 264,000 $13.75 11/23/2021
Series FF 12/8/2016 68,048 $3.91 12/1/2021
Series CC 12/8/2016 680,480 $5.00 12/8/2021
Series HH 2/23/2017 20,000 $3.13 2/16/2022 [likely exercised|
Series AA 8/26/2016 200,000 $13.75 2/22/2022
Series JJ 3/14/2017 30,000 $3.13 3/8/2022 [likely exercised|
Series LL 4/30/2017 26,398 $3.59 4/30/2022
Series MM 6/22/2017 893,491 $1.86 6/22/2022 [likely exercised|
Series NN 7/24/2017 539,300 $2.52 7/24/2022 [likely exercised|
Series OO 7/31/2017 60,000 $2.52 7/31/2022 [likely exercised|
Series QQ 8/22/2017 87,500 $2.50 8/22/2022 [likely exercised|
Series GG 2/23/2017 400,000 $3.00 8/23/2022 [likely exercised|
Series II 3/14/2017 600,000 $3.00 9/14/2022 [likely exercised|
Series RR 10/30/2017 583,057 $1.65 10/30/2022 [likely exercised|
Series KK 5/3/2017 395,970 $3.04 11/3/2022 [likely exercised|
Series SS 12/19/2017 1,289,478 $2.09 12/18/2022 [likely exercised|
Series TT 2/5/2018 1,875,860 $2.24 2/5/2023 [likely exercised|
Series PP 8/28/2017 1,750,000 $2.30 2/28/2023 [likely exercised|
*
The PR of being hollywood saxphonist cool is because the compositional gifts are also artistic.
http://neuroblogsdaily.com
http://andyadkins.com
Recent CVM News
- CEL-SCI Appoints Robert Watson as Chairperson of the Board • Business Wire • 07/08/2024 01:15:00 PM
- CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population • Business Wire • 06/18/2024 12:00:00 PM
- Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor • Business Wire • 06/06/2024 11:00:00 AM
- CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results • Business Wire • 05/16/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:17:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 01:04:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 05:07:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 01:19:04 PM
- CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer • Business Wire • 05/08/2024 01:00:00 PM
- CEL-SCI Appoints Mario Gobbo to Its Board of Directors • Business Wire • 04/23/2024 01:00:00 PM
- CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology • Business Wire • 03/19/2024 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/07/2024 04:33:42 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/07/2024 04:33:13 PM
- CEL-SCI Corporation Issues Letter to Shareholders • Business Wire • 03/06/2024 01:45:00 PM
- CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results • Business Wire • 02/15/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:31:12 PM
- CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock • Business Wire • 02/13/2024 05:00:00 PM
- CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock • Business Wire • 02/09/2024 01:30:00 PM
- CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug • Business Wire • 02/06/2024 02:00:00 PM
- European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine® • Business Wire • 01/31/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:06:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:03:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:00:11 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM